Flash Finance

Medicamen Biotech LimitedMEDICAMEQCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹284.45
MCap ₹386 Cr · P/E 1.0
Medicamen Biotech Limited — Stock analysis & AI research Medicamen Biotech Limited — Seasonality — best & worst months Medicamen Biotech Limited — Technical setup — score, trend, support & resistance Medicamen Biotech Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹48 Cr
Sales · Jun 2026
+11.3% YoY
₹4 Cr
Operating Profit · Jun 2026
-6.3% YoY
9.0%
OPM % · Jun 2026
-15.9% YoY
₹2 Cr
Net Profit · Jun 2026
+15.3% YoY
—
EPS · Jun 2026

📝 Medicamen Biotech Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Medicamen Biotech Limited reported revenue of ₹48 crore for the quarter ended June 2026 (Q1 FY27), up 11.3% from ₹43 crore in the same quarter last year, and down 21.0% sequentially over the March 2026 quarter.

Net profit rose 15.3% year-on-year to ₹2 crore, from ₹2 crore.

Operating profit stood at ₹4 crore — an operating margin (OPM) of 9.0%, compared with 10.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Medicamen Biotech Limited posted revenue of ₹9,512 crore, a growth of 5751.8% over FY25, with a net profit of ₹381 crore (up 3308.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹9,516 crore with a net profit of ₹381 crore.

Valuation snapshot

At the current price of ₹284.45, MEDICAMEQ has a market capitalisation of ₹386 crore and a trailing P/E of about 1.0.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 14th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 40.46%, foreign institutional investors (FIIs) 0.10%, domestic institutional investors (DIIs) 0.00%, the government 0.05%, public shareholders 59.39% of Medicamen Biotech Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹386 Cr
Current Price ?
₹284.4
P/E ?
1.01below ind
Industry P/E ?
21.30
P/B ?
1.40
P/S ?
0.04
P/FCF ?
-10.15
Enterprise Value ?
₹434 Cr
EV/EBITDA ?
0.45
PEG ?
N/A
Earnings Yield ?
136.2%
Dividend Yield ?
0.33%
Profitability & Returns
Sales (TTM) ?
₹9,516 Cr
OPM ?
10.1%
Profit after tax (TTM) ?
₹381 Cr
EPS (TTM) ?
₹281.06
ROCE ?
5.0%
ROE ?
138.1%
ROA ?
102.5%
Growth
Sales — latest qtr ?
₹48 Cr
PAT — latest qtr ?
₹2 Cr
YoY qtr sales growth ?
11.3%
YoY qtr profit growth ?
15.3%
Sales growth (3y) ?
12%
Sales growth (5y) ?
12%
Profit growth (3y) ?
-13%
Profit growth (5y) ?
-4%
Financial Health
Debt ?
₹48 Cr
Debt to Equity ?
0.17
Interest Coverage ?
3.0
Current Ratio ?
N/A
Ownership
Promoter holding ?
40.46%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
19.2%
Return 6 months ?
10.2%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 394244474743454530434,7174,6916148 +11.3% -21.0%
Operating Profit 6755635720551643854 -6.3% -20.3%
Other Income 0011110000375321 +83.2% -50.5%
Interest 1111211131999701 -28.1% +118.1%
Depreciation 222222327218618322 -0.8% +3.3%
Profit Before Tax 4523322410226821153 +20.7% -49.2%
Net Profit 441221137221116342 +15.3% -58.5%
EPS 3.073.121.171.601.610.630.712.301.901.181.561.612.85— — —
OPM % 16.8% 16.6% 10.7% 10.5% 12.2% 8.0% 11.9% 14.9% 68.3% 10.7% 10.9% 9.3% 9.0% 9.0% -15.9% +0.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹163 Cr ₹9,512 Cr ₹9,516 Cr +5751.8%
Operating Profit ₹36 Cr ₹963 Cr ₹963 Cr +2598.0%
OPM % 21.96% 10.13% 10.12% -53.9%
NPM % 6.88% 4.01% 4.01% -41.7%
Other Income ₹2 Cr ₹93 Cr ₹93 Cr +6065.0%
Depreciation ₹14 Cr ₹372 Cr ₹372 Cr +2621.8%
Interest ₹6 Cr ₹198 Cr ₹197 Cr +3390.8%
EBIT ₹22 Cr ₹591 Cr ₹591 Cr +2583.3%
PBT ₹18 Cr ₹487 Cr ₹487 Cr +2621.3%
Tax ₹6 Cr ₹105 Cr ₹105 Cr +1756.8%
Net Profit ₹11 Cr ₹381 Cr ₹381 Cr +3308.0%
EPS ₹5.54 ₹7.20 ₹6.02 +30.0%
Material Cost ₹50 Cr ₹4,390 Cr ₹4,388 Cr +8647.9%
Employee Cost ₹16 Cr ₹1,728 Cr ₹1,730 Cr +10811.7%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 13131314 +7.7%
Reserves 181194200262 +31.0%
Borrowings 26313448 +41.2%
Other Liabilities 59565049 -2.0%
Total Liabilities 279295297372 +25.3%
Fixed Assets 93928785 -2.3%
CWIP 0000 —
Investments 0000 —
Other Assets 186203210287 +36.7%
Total Assets 279295297372 +25.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -6-7-8-33 -312.5%
Cash from Investing Activity -6-6-1-3 -200.0%
Cash from Financing Activity 296-164 +6500.0%
Net Cash Flow 17-6-1128 +354.5%
Free Cash Flow -13-13-10-38 -280.0%
CFO/OP -13%-16%-47%-159% -238.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 169112155151 -2.6%
Inventory Days 228234268251 -6.3%
Days Payable 241154184144 -21.7%
Cash Conversion Cycle 156193239259 +8.4%
Working Capital Days 156123186193 +3.8%
ROCE % 10%8%6%5% -16.7%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 40.46%40.46%40.46%40.46% +0.0%
FIIs 0.00%0.05%0.02%0.10% +400.0%
DIIs 0.64%0.59%0.44%0.00% -100.0%
Government 0.05%0.05%0.05%0.05% +0.0%
Public 58.83%58.84%59.02%59.39% +0.6%
No. of Shareholders 10,80811,17710,96710,806 -1.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Medicamen Biotech Limited's revenue in Q1 FY27?
Medicamen Biotech Limited reported revenue of ₹48 crore for the quarter ended June 2026 (Q1 FY27), up 11.3% from ₹43 crore in the same quarter last year, and down 21.0% sequentially over the March 2026 quarter.
What was Medicamen Biotech Limited's net profit in Q1 FY27?
Net profit rose 15.3% year-on-year to ₹2 crore, from ₹2 crore.
What is MEDICAMEQ's market capitalisation and P/E ratio?
At the current price of ₹284.45, MEDICAMEQ has a market capitalisation of ₹386 crore and a trailing P/E of about 1.0.
Who owns Medicamen Biotech Limited? (shareholding pattern)
As of Mar 2026, promoters held 40.46%, foreign institutional investors (FIIs) 0.10%, domestic institutional investors (DIIs) 0.00%, the government 0.05%, public shareholders 59.39% of Medicamen Biotech Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI